FrançaisNeurocrine Biosciences (NBIX): financial analysis & fundamentals
📈 See the interactive version (live chart) →
Valuation & profitability
| Metric | Value | What it means |
|---|---|---|
| P/E (price / earnings) | 22.9 | The higher, the more growth the market expects. |
| Forward P/E | 13.0 | On next year's expected earnings. Lower than current P/E = rising earnings. |
| PEG (P/E ÷ growth) | 0.74 | Below 1 = cheap given growth; above 2 = expensive. |
| Net margin | 21% | Share of revenue that ends up as profit. |
| Revenue growth | 40% | Pace of revenue growth. |
| Price-to-book | 4.3 | Price relative to book value. |
| Market cap | $15.8 B | Total market value of the company. |
| Dividend yield | — | No dividend currently. |
Income statement (by year)
| Year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2022 | $1.5 B | $154 M | 10% |
| 2023 | $1.9 B | $250 M | 13% |
| 2024 | $2.4 B | $341 M | 14% |
| 2025 | $2.9 B | $479 M | 17% |
📊 Open the interactive Neurocrine Biosciences page (charts, live news) →
Frequently asked questions
Is Neurocrine Biosciences stock expensive?
Neurocrine Biosciences has a P/E of 22.9 (forward P/E 13.0) and a PEG of 0.74. A PEG below 1 is rather cheap given growth, above 2 is expensive. Verdict: rather cheap given growth.
What is Neurocrine Biosciences's net margin?
Neurocrine Biosciences's net margin is about 21% — the share of revenue that ends up as net profit.
What is Neurocrine Biosciences's revenue?
Latest known revenue: $2.9 B for net income of $479 M. The year-by-year breakdown is in the income statement above.
What is Neurocrine Biosciences's market cap?
Neurocrine Biosciences (NBIX) has a market cap of about $15.8 B.
Does Neurocrine Biosciences pay a dividend?
No, Neurocrine Biosciences does not currently pay a dividend (it reinvests earnings).
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Data: Yahoo Finance, recomputed by JPI Invest. A stock can be « cheap » for a bad reason.